Third Position Detail definition

Third Position Detail means a Detail in which the applicable pharmaceutical product is Detailed in the third position (i.e., no more than two (2) other products are presented to or discussed with the healthcare professional before the Product) and/or the third most predominant portion of time is devoted to the Detailing of such pharmaceutical product.
Sample 1Sample 2Sample 3
Third Position Detail means a Detail by an Elan Professional Sales Representative to a Target Healthcare Professional in the Territory in which the Product is Detailed in the third or higher position.
Sample 1
Third Position Detail means a Detail in which the applicable pharmaceutical product is Detailed in the third position (i.e., no more than two (2) other products are presented to or discussed with the healthcare professional before the Product) and/or the third most predominant portion of time is devoted to the Detailing of such pharmaceutical product. 1.115 “Transition Period” has the meaning set forth in Section 14.5 (Transition Period). 1.116 “United States” or “U.S.” means the United States of America, including its territories and possessions (including the District of Columbia and Puerto Rico). 1.117 “United States Brand Plan” means, with respect to the Product, the United States-specific strategic and high-level tactical, cross-functional Commercialization plan jointly developed by Novartis and Amgen (including through the JUSLT) for the Product in the United States, including the United States Payer Plan and the United States Pricing Policy. 1.118 “United States Novartis Patents and Trademarks” has the meaning set forth in Section 9.2.3 (Novartis Primary Prosecution). 1.119 “United States Patents and Trademarks” has the meaning set forth in Section 9.2.1 (Amgen Primary Prosecution). 1.120 “United States Payer Plan” means, with respect to the Product, the United States-specific plan for the Product jointly prepared by Novartis and Amgen (including through the JUSLT) that sets forth the strategic direction, positioning, value proposition, pricing strategy, value evidence generation plan, economic modeling strategy and reimbursement for the Product in the United States. Amgen Ref. No. 2017747574 Page 13 Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange Commission. 1.121 “United States Pricing Policy” means, with respect to the Product, the United States-specific plan for the Product jointly prepared by Amgen and Novartis (including through the JUSLT) that sets forth the proposed price range, rebates and discounts range, target population and reimbursement target for the Product in the United States. 1.122 “United States Senior Officers” means the [*] for Novartis and the [*] for Amgen. 1.123 “US Biosimilar Entry Date” has the meaning set forth in Section 8.3.2 (Royalty Reduction for Biosimilar Competition). 1.124 “US Collaboration” has the meaning set forth in Section 2.1 (Conduct of the Collaboration). 1.125 “US Collaboration Team” or “USCT” has t...
Sample 1

Examples of Third Position Detail in a sentence

  • For the avoidance of doubt, the foregoing sentence does not prohibit either Party’s Sales Representatives from detailing any product other than a Licensed Product as a Third Position Detail.

Related to Third Position Detail

  • Queue Position means the priority assigned to an Interconnection Request, a Completed Application, or an Upgrade Request pursuant to applicable provisions of Tariff, Part VI.

  • Covered position means a position in which the employee must be a member of the retirement

  • Matched Positions for CFD trading shall mean Long and Short Positions of the same Transaction Size opened on the Client Account for the same CFD.

  • Net Long Position means: such shares of Common Stock Beneficially Owned, directly or indirectly, that constitute such person’s net long position as defined in Rule 14e-4 under the Exchange Act mutatis mutandis, provided that “Net Long Position” shall not include any shares as to which such person does not have the right to vote or direct the vote; and the terms “person” or “persons” shall mean any individual, corporation (including not-for-profit), general or limited partnership, limited liability or unlimited liability company, joint venture, estate, trust, association, organization or other entity of any kind or nature.

  • Net Sell Position means the amount of Net Obligation when Net Obligation is negative.

  • Eligible position or "full-time job" means a full-time position

  • Long Position means a buy position that appreciates in value if market prices increase. In respect of Currency Pairs: buying the Base Currency against the Quote Currency.

  • Qualifying position means one or more jobs with one or more participating public em-

  • Comparable Position means a position where:

  • Assigned Annual Special Tax means the Special Tax of that name described in Section D.

  • continuing professional development means the continuing professional development contemplated in section 32;

  • Shielded position means the location within the radiographic exposure device or storage container which, by manufacturer's design, is the proper location for storage of the sealed source.

  • Opium poppy means the plant of the species Papaver somniferum L., except its seeds.

  • Cash Position means the Company’s level of cash and cash equivalents.

  • Safety-sensitive position means a job, including any supervisory or management position, in which an impairment caused by drug or alcohol usage would threaten the health or safety of any person.

  • Competitive Position means any employment with a Competitor in which Executive will use or is likely to use any Confidential Information or Trade Secrets, or in which Executive has duties for such Competitor that relate to Competitive Services and that are the same or similar to those services actually performed by Executive for the Company;

  • Call Equivalent Position shall have the meaning set forth in Rule 16a-1(b) under the Exchange Act.

  • Ineligible position means any position which does not

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Additional SDU Study means a deliverability study that a Developer may elect to pursue as that term is defined in OATT Section 25 (OATT Attachment S). For purposes of Section 23.4.5 of this Attachment H, “Affiliated Entity” shall mean, with respect to a person or Entity:

  • Synthetic Long Position means any option, warrant, convertible security, stock appreciation right, swap agreement or other security, contract right or derivative position, whether or not presently exercisable, that has an exercise or conversion privilege or a settlement payment or mechanism at a price related to the value of Common Stock or a value determined in whole or part with reference to, or derived in whole or in part from, the value of Common Stock and that increases in value as the value of Common Stock increases or that provides to the holder an opportunity, directly or indirectly, to profit or share in any profit derived from any increase in the value of Common Stock, in any case without regard to whether (i) such derivative conveys any voting rights in such securities to such Person or any of such Person’s Affiliates or Associates, (ii) such derivative is required to be, or capable of being, settled through delivery of such securities, or (iii) such Person or any of such Person’s Affiliates or Associates may have entered into other transactions that hedge the economic effect of such derivative. A Synthetic Long Position shall not include any interests, rights, options or other securities set forth in Rule 16a-1(c)(1)-(5) or (7) of the General Rules and Regulations under the Exchange Act.

  • Peak tube potential means the maximum value of the potential difference across the x-ray tube during an exposure.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Derivative Positions means, with respect to a stockholder or any Stockholder Associated Person, any derivative positions including, without limitation, any short position, profits interest, option, warrant, convertible security, stock appreciation right, or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of shares of the Corporation or with a value derived in whole or in part from the value of any class or series of shares of the Corporation, whether or not such instrument or right shall be subject to settlement in the underlying class or series of capital stock of the Corporation or otherwise and any performance-related fees to which such stockholder or any Stockholder Associated Person is entitled based, directly or indirectly, on any increase or decrease in the value of shares of capital stock of the Corporation;

  • Phase II Study means a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.